Montmorillonite as an Anti-Tuberculosis Rifampicin Drug Carrier: DFT and Experimental Study

被引:0
|
作者
Eva Scholtzová
Luboš Jankovič
Daniel Tunega
机构
[1] Slovak Academy of Sciences,Institute of Inorganic Chemistry
[2] University of Natural Resources and Life Sciences Vienna,Institute for Soil Research, Department of Forest and Soil Sciences
来源
Clays and Clay Minerals | 2023年 / 71卷
关键词
DFT-D3; Drug carrier; Hydrogen bonds; Molecular dynamics; Montmorillonite; Rifampicin;
D O I
暂无
中图分类号
学科分类号
摘要
A hybrid of montmorillonite (Mnt) and rifampicin (RIF) was synthesized and the structure and stability of the drug carrier system clarified. Density functional theory calculations involving dispersion corrections (DFT-D3) were performed to characterize interactions acting in the interlayer space of montmorillonite intercalated with rifampicin. The structure and stability of the RIF-Mnt intercalated complex were determined. Calculations revealed the deformation of the molecular structure of rifampicin after intercalation into the Mnt interlayer space due to the clay environment. The ansa chain of RIF was bent in the interlayer space compared with the structure of the RIF molecule in the monocrystal. RIF was keyed into the Mnt surface by means of numerous hydrogen bonds of weak to moderate strength. The calculated vibrational spectrum from ab initio molecular dynamics (AIMD) was in good agreement with the FTIR measured spectra and helped to analyze the overlapped vibrational bands. Based on analysis of structural stability, theoretical calculations revealed that Mnt is a suitable drug carrier for delayed release of the RIF drug. Batch adsorption experiments showed the large adsorption capacity of montmorillonite for RIF.
引用
收藏
页码:229 / 241
页数:12
相关论文
共 50 条
  • [21] HEPATIC TOXICITY OF ANTI-TUBERCULOSIS REGIMENS CONTAINING ISONIAZID, RIFAMPICIN AND PYRAZINAMIDE
    GIRLING, DJ
    TUBERCLE, 1978, 59 (01): : 13 - 32
  • [22] Target Identification in Anti-Tuberculosis Drug Discovery
    Capela, Rita
    Felix, Rita
    Clariano, Marta
    Nunes, Diogo
    Perry, Maria de Jesus
    Lopes, Francisca
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (13)
  • [23] FDA approves new anti-tuberculosis drug
    不详
    LEPROSY REVIEW, 1999, 70 (02) : 240 - 240
  • [24] Control of anti-tuberculosis drug resistance in Botswana
    Talbot, EA
    Kenyon, TA
    Mwasekaga, MJ
    Moeti, TL
    Mallon, V
    Binkin, NJ
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2003, 7 (01) : 72 - 77
  • [25] ANTI-TUBERCULOSIS DRUG RESISTANCE IN WEST OF Iran
    Mohajeri, Parviz
    Norozi, Baharak
    Farahani, Abbas
    IRANIAN JOURNAL OF PUBLIC HEALTH, 2014, 43 : 269 - 269
  • [26] A new concept for anti-tuberculosis drug discovery
    Grzelak, E. M.
    Choules, M.
    Hwang, C. H.
    Nam, J. W.
    Mulugeta, S. G.
    McAlpine, J. B.
    Cai, G.
    Gao, W.
    Lankin, D. C.
    Napolitano, J. G.
    Suh, J. W.
    Yang, S. H.
    Cheng, J.
    Kim, J.
    Cho, S. H.
    Pauli, G. F.
    Franzblau, S. G.
    Jaki, B. U.
    PLANTA MEDICA, 2014, 80 (10) : 759 - 759
  • [27] Oxadiazole scaffolds in anti-tuberculosis drug discovery
    De, Suparna S.
    Khambete, Mihir P.
    Degani, Mariam S.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2019, 29 (16) : 1999 - 2007
  • [28] ANTI-TUBERCULOSIS DRUG RESISTANCE IN SOUTHEAST OF TURKEY
    Dal, Tuba
    Ozcan, Nida
    Tekin, Recep
    Tekin, Alicem
    Celen, Mustafa Kemal
    Ozekinci, Tuncer
    Dal, T.
    Ozcan, N.
    Tekin, R.
    Tekin, A.
    Celen, M. K.
    Ozekinci, T.
    ACTA MEDICA MEDITERRANEA, 2013, 29 (01): : 41 - 46
  • [29] Increasing anti-tuberculosis drug resistance in the UK
    Kruijshaar, M. E.
    Watson, J. M.
    Drobniewski, F.
    Anderson, C.
    Magee, J. G.
    Smith, E. G.
    Abubakar, I.
    THORAX, 2007, 62 : A4 - A5
  • [30] Anti-tuberculosis drug resistance in Dohuk, Iraq
    Merza, Muayad A.
    Farnia, Parissa
    Masjedi, Mohammad Reza
    Ridell, Malin
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2010, 14 (09) : 1213 - 1214